Get the Stockscreener App
17.16
1.66%
-0.29
Pre-market:
17.48
0.32
+1.86%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $17.16, with a volume of 378.21K.
It is down -1.66% in the last 24 hours and down -5.40% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
See More
Previous Close:
$17.45
Open:
$17.45
24h Volume:
378.21K
Relative Volume:
0.81
Market Cap:
$760.94M
Revenue:
$159.01M
Net Income/Loss:
$-21.72M
P/E Ratio:
-33.00
EPS:
-0.52
Net Cash Flow:
$-20.63M
1W Performance:
-3.43%
1M Performance:
-5.40%
6M Performance:
+24.44%
1Y Performance:
+113.17%
1-Day Range:
$17.05
$17.65
1-Week Range:
$16.79
$18.28
52-Week Range:
$5.55
$21.00
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
17.16 | 760.94M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth By Investing.com - Investing.com Canada
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com
Cantor maintains AxoGen stock target at $24, bullish on growth plan - Investing.com Australia
Cantor maintains AxoGen stock target at $24, bullish on growth plan By Investing.com - Investing.com South Africa
(AXGN) Technical Data - Stock Traders Daily
Principal Financial Group Inc. Boosts Stock Position in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for AxoGen (NASDAQ:AXGN) - Defense World
Axogen director Amy McBride sells $100,100 in stock By Investing.com - Investing.com Canada
Insider Sell: Amy Wendell Sells 5,000 Shares of Axogen Inc (AXGN) - GuruFocus.com
Axogen director Amy McBride sells $100,100 in stock - Investing.com India
Analyst Expectations For Axogen's Future - Benzinga
Cantor Fitzgerald maintains AxoGen stock overweight rating By Investing.com - Investing.com Australia
AxoGen’s Strategic Growth and Market Positioning: Buy Rating Affirmed by Caitlin Cronin - TipRanks
Cantor Fitzgerald maintains AxoGen stock overweight rating - Investing.com India
Citizens JMP reiterates AxoGen stock with $26 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates AxoGen stock with $26 target - Investing.com
14,285 Shares in AxoGen, Inc. (NASDAQ:AXGN) Bought by Y Intercept Hong Kong Ltd - Defense World
AxoGen’s Strategic Market Positioning and Anticipated BLA Approval Drive Buy Rating - TipRanks
AxoGen Unveils Strategic Priorities for 2025-2028 - TipRanks
AxoGen, Inc. (NASDAQ:AXGN) Shares Purchased by New York State Common Retirement Fund - Defense World
Leerink Partnrs Estimates AxoGen FY2029 Earnings - Defense World
Cantor Fitzgerald Decreases Earnings Estimates for AxoGen - Defense World
FY2025 EPS Estimates for AxoGen Lowered by Cantor Fitzgerald - MarketBeat
AxoGen (NASDAQ:AXGN) Posts Quarterly Earnings Results - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for AxoGen (NASDAQ:AXGN) Stock - Defense World
Investor Network: AxoGen, Inc. to Host Earnings Call - ACCESS Newswire
AxoGen Reports Strong Growth and Positive Outlook - TipRanks
Canaccord Genuity Group Raises AxoGen (NASDAQ:AXGN) Price Target to $26.00 - MarketBeat
AxoGen Q4 2024 Earnings Preview - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q4 2024 Earnings Call Transcript - Insider Monkey
The 12% return this week takes Axogen's (NASDAQ:AXGN) shareholders three-year gains to 122% - Simply Wall St
JMP lifts AxoGen stock price target to $26 from $20 By Investing.com - Investing.com South Africa
JMP lifts AxoGen stock price target to $26 from $20 - Investing.com
AxoGen price target raised to $26 from $20 at Citizens JMP - TipRanks
Axogen Q4 2024 revenue up 15.1% to USD 49.4M - Medical Buyer
Leerink raises AxoGen stock price target to $25, maintains Outperform By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Raymond James lifts AxoGen stock target to $25, maintains Outperform By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... - Yahoo Finance
Axogen, Inc. To Host Analyst & Investor Day on March 4th - GlobeNewswire
Canaccord lifts AxoGen stock price target to $26, maintains buy rating By Investing.com - Investing.com South Africa
Canaccord lifts AxoGen stock price target to $26, maintains buy rating - Investing.com India
Raymond James lifts AxoGen stock target to $25, maintains Outperform - Investing.com
Axogen Inc earnings beat by $0.04, revenue topped estimates - Investing.com Canada
AxoGen: Q4 Earnings Snapshot - mySA
AxoGen stock price target raised to $24 by Cantor Fitzgerald - Investing.com Canada
Leerink raises AxoGen stock price target to $25, maintains Outperform - Investing.com India
Axogen stock soars to 52-week high, hits $19.25 - Investing.com
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):